Healthcare conglomerate Johnson & Johnson (J&J) is dismissing 56 employees at its global corporate headquarters in New Brunswick, New Jersey. According to formal state Worker Adjustment and Retraining Notification (WARN) filings, the targeted layoffs will take statutory effect on August 21. The round represents the initial wave of terminations executed by J&J within the state this year, following a larger workforce reduction at the same New Brunswick complex that eliminated 231 jobs in the fall of 2024. A J&J corporate spokesperson confirmed that the current job cuts are tied directly to the firm’s planned divestiture of its orthopedics business from the core MedTech sector, an operational spin-off first revealed in October last year. The manufacturer is focusing on managing stranded costs and improving operating margins to enable continued capital investment in clinical innovation.
The baseline consolidation data tracking the wider biopharmaceutical layoff wave in New Jersey outlines the following metrics:
-
Novartis Staff Downsizing: Last week, Swiss drugmaker Novartis slashed its workforce by 76 individuals at its U.S. operational headquarters in East Hanover. This transaction marked the company’s third round of layoffs in as many months at that facility, following two prior consecutive sequences that handed out pink slips to 174 employees. The measures tie back to a macro restructuring blueprint instituted in 2022 designed to eliminate 8,000 jobs globally.
-
Bristol Myers Squibb (BMS) Fiscal Adjustments: Spanning two separate elimination phases this year at its operational footprint in Lawrenceville, BMS has downsized its local staff by 453 workers. Since the commencement of 2025, BMS has trimmed more than 1,700 personnel from its wider payroll as part of a strategic program to capture over $2 billion in cumulative savings through 2027.
-
M&A-Driven Attrition: Earlier this month, New Jersey-based Amicus Therapeutics executed a workforce reduction affecting 58 employees. The operational downsizing materialized shortly after the biopharma entity was completely absorbed by BioMarin under a definitive $4.8 billion corporate buyout.
Source: https://www.fiercepharma.com/pharma/jj-separates-its-orthopedics-business-it-lays-56-new-jersey